Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 3, 2003, Pages 1117-1125

  Schlötzer Schrehardt, Ursula ^a   Lommatzsch, Jürgen ^a   Küchle, Michael ^a   Konstas, Anastasios G P ^b   Naumann, Gottfried O H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME REGULATION; HUMAN; MAJOR CLINICAL STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOEXFOLIATION; WESTERN BLOTTING; ZYMOGRAPHY;

AGED; AQUEOUS HUMOR; BLOTTING, WESTERN; CATARACT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXFOLIATION SYNDROME; GLAUCOMA, OPEN-ANGLE; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0037337851     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0365     Document Type: Article

References (49)

1. Naumann GOH, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologists. Ophthalmology. 1998;105:951-968.
2. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265-315.
3. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma. 1996;3:176-178.
4. Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Naumann GOH. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet, 2001;357:359-360.
5. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol. 1997; 124:685-687.
6. Streeten BW. Aberrant synthesis and aggregation of elastic tissue components in pseudoexfoliation fibrillopathy: a unifying concept. New Trends Ophthalmol. 1993;8:187-196.
7. Schlötzer-Schrehardt U, von der Mark K, Sakai LY, Naumann GOH. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci. 1997;38: 970-984.
8. Schlötzer-Schrehardt U, Naumann GOH. Trabecular meshwork in pseudoexfoliation syndrome with and without open-angle glaucoma. Invest Ophthalmol Vis Sci. 1995;36:1750-1764.
9. Schlötzer-Schrehardt U, Küchle M, Naumann GOH. Mechanisms of glaucoma development in pseudoexfoliation syndrome. In: Gramer E, Grehn F. eds. Pathogenesis and Risk Factors of Glaucoma. Heidelberg, Germany: Springer; 1999:34-49.
10. Rohen JW. Why is intraocular pressure elevated in chronic simple glaucoma? Ophthalmology. 1983;90:758-765.
11. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of "plaque material" in the inner and outer wall of Schlemm's canal in normal and glaucomatous eyes. Exp Eye Res. 1986;42:443-455.
12. Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276-285.
13. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
14. Woessner JF Jr. The family of matrix metalloproteinases. Ann NY Acad Sci. 1994;732:11-21.
15. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
16. Vadillo-Ortega F, Gonzalez-Avila G, Chevez P, Abramham CR, Montano M, Selman-Lama M. A latent collagenase in human aqueous humor. Invest Ophthalmol Vis Sci. 1989;30:332-335.
17. Ando H, Twining SS, Yue BYJT, et al. MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541-3548.
18. DiGirolamo N, Verma MJ, McCluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060-1068.
19. Kee C, Son S, Ahn BH. The relationship between gelatinase A activity in aqueous humor and glaucoma. J Glaucoma. 1999;8:51-55.
20. El-Shabrawi Y, Christen WG, Foster CS. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1β, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res. 2000;20:211-214.
21. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol. 1994;144:528-537.
22. Herbst H, Wege T, Milani S, et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol. 1997;150:1647-1659.
23. Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol. 1998;153:1895-1902.
24. De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998;39:1256-1260.
25. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:1524-1529.
26. Sethi CS, Bailey TA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol. 2000;84:654-666.
27. Tamiya S, Wormstone IM, Marcantonio JM, Gavrilovic J, Duncan G. Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp Eye Res. 2000;71:591-597.
28. DiGirolamo N, McCluskey P, Lloyd A, Coroneo MT, Wakefield D. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2000;41: 671-679.
29. Dushku N, John MK, Schultz GS, Reid TW. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001;119:695-706.
30. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703-1709.
31. Maliszewska M, Mäder M, Schöll U, et al. Development of an ultrasensitive enzyme immunoassay for the determination of matrix metalloproteinase-9 (MMP-9) levels in normal human cerebrospinal fluid. J Neuroimmunol. 2001;116:233-237.
32. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
33. Howard EW, Banda MJ. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. J Biol Chem. 1991;266:17972-17977.
34. Parks WC, Mecham RP. Matrix Metalloproteinases. San Diego: Academic Press; 1998.
35. Hembry RM, Ehrlich HP. Immunolocalization of collagenase and tissue inhibitor of metalloproteinases (TIMP) in hypertrophic scar tissue. Br J Dermatol. 1986;115:409-420.
36. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol. 1994;103:359-363.
37. Arakawa M, Hatamochi A, Mori Y, Mori K, Ueki H, Moriguchi T. Reduced collagenase gene expression in fibroblasts from hypertrophic scar tissue. Br J Dermatol. 1996;134:863-868.
38. Matsuo T, Okada Y, Shiraga F, Yanagawa T. TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol. 1998;42: 377-380.
39. Fini EF, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31:1779-1788.
40. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
41. Küchle M, Nguyen NX, Hannappel E, Naumann GOH. The bloodaqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res. 1995;27(suppl 1):136-142.
42. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann N Y Acad Sci. 1994:73251-73264.
43. Edwards DR, Leco KJ, Beaudry PP, Atadja PW, Veillette C, Riabowol KT. Differential effects of transforming growth factorbeta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp Gerontol. 1996;31:207-223.
44. Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
45. Schlötzer-Schrehardt U, Zenkel M, Küchle M, Sakai LY, Naumann GOH. Role of transforming growth factor-β1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
46. Koliakos GG, Schlötzer-Schrehardt U, Konstas AGP, Bufidis T, Georgiadis N, Dimitriadou A. Transforming and insulin-like growth factors in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:482-487.
47. Tripathi RC, Li J, Chan WFA, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-β2. Exp Eye Res. 1994;59:723-728.
48. Helbig H, Schlötzer-Schrehardt U, Noske W, Kellner U, Foerster M, Naumann GOH. Anterior-chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger J Ophthalmol. 1994;3:148-153.
49. Norman JT, Clark IM, Garcia PL. Regulation of TIMP-1 expression by hypoxia in kidney fibroblasts. Ann N Y Acad Sci. 1999;878: 503-505.